These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31206362)

  • 1. Betahistine-Associated Weight Loss and Improved Cognitive and Negative Symptoms: Domain in Early-Onset Schizophrenia.
    Naguy A; AlShalabi SR; AlKhadhari S
    Am J Ther; 2019; 26(6):e790-e792. PubMed ID: 31206362
    [No Abstract]   [Full Text] [Related]  

  • 2. A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain.
    Barak N; Beck Y; Albeck JH
    J Clin Psychopharmacol; 2016 Jun; 36(3):253-6. PubMed ID: 27028981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Festina Lente: Betahistine for Clozapine-Associated Weight Gain: A Case Report.
    Suhas S; Shivani S; Singh GK; Venkatasubramanian G
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):332-333. PubMed ID: 33843821
    [No Abstract]   [Full Text] [Related]  

  • 4. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
    Poyurovsky M; Fuchs C; Pashinian A; Levi A; Weizman R; Weizman A
    Psychopharmacology (Berl); 2013 Apr; 226(3):615-22. PubMed ID: 23239133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients.
    Poyurovsky M; Pashinian A; Levi A; Weizman R; Weizman A
    Int Clin Psychopharmacol; 2005 Mar; 20(2):101-3. PubMed ID: 15729086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
    Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
    Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications.
    Lian J; Huang XF; Pai N; Deng C
    Pharmacol Res; 2016 Apr; 106():51-63. PubMed ID: 26892184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.
    Deng C; Lian J; Pai N; Huang XF
    J Psychopharmacol; 2012 Sep; 26(9):1271-9. PubMed ID: 22695490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Betahistine decreases olanzapine-induced weight gain and somnolence in humans.
    Barak N; Beck Y; Albeck JH
    J Psychopharmacol; 2016 Mar; 30(3):237-41. PubMed ID: 26839321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways.
    Lian J; Huang XF; Pai N; Deng C
    Psychoneuroendocrinology; 2014 Oct; 48():77-86. PubMed ID: 24992721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight Loss During Atomoxetine Add-on to Clozapine-Responsive Schizophrenia.
    Naguy A; Alamiri B; Khraibut B
    Am J Ther; 2018; 25(6):e774-e775. PubMed ID: 29782344
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial.
    Barak N; Greenway FL; Fujioka K; Aronne LJ; Kushner RF
    Int J Obes (Lond); 2008 Oct; 32(10):1559-65. PubMed ID: 18698316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia: A Case Report.
    Boland X; Chhabra P
    J Psychiatr Pract; 2019 Mar; 25(2):135-138. PubMed ID: 30849062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of betahistine repeated administration on a weight gain and selected metabolic parameters in the model of excessive eating in rats.
    Mika K; Szafarz M; Sapa J; Kotańska M
    Biomed Pharmacother; 2021 Sep; 141():111892. PubMed ID: 34229247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zonisamide-induced weight loss in schizophrenia: case series.
    Yang J; Lee MS; Joe SH; Jung IK; Kim SH
    Clin Neuropharmacol; 2010; 33(2):104-6. PubMed ID: 19935403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involuntary Facial Twitching in a Patient with Schizophrenia on Treatment with Long Acting Injectable Olanzapine.
    Mustafa FA; Nayar A
    Psychopharmacol Bull; 2019 Jun; 49(2):63-64. PubMed ID: 31308585
    [No Abstract]   [Full Text] [Related]  

  • 17. A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.
    Srisurapanont M; Suttajit S; Likhitsathian S; Maneeton B; Maneeton N
    Sci Rep; 2021 Apr; 11(1):7583. PubMed ID: 33828206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
    Sun L; McDonnell D; von Moltke L
    Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early prediction of olanzapine-induced weight gain for schizophrenia patients.
    Lin CH; Lin SC; Huang YH; Wang FC; Huang CJ
    Psychiatry Res; 2018 May; 263():207-211. PubMed ID: 29574355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight loss during therapy with olanzapine orally disintegrating tablets: two case reports.
    Kozumplik O; Uzun S; Jakovljević M
    Psychiatr Danub; 2009 Mar; 21(1):72-4. PubMed ID: 19270625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.